The last line of the announcement before the CEO quote is interesting and worth contemplating.
"With a number of COVID-19/influenza tests having entered the market in the last 12 months and a declining use of rapid antigen tests (RATs) for
COVID-19, Lumos will monitor its sales and marketing investment for ViraDx to ensure that it is supported by robust end-user demand."
1. Many competitors
2. Decling demand for Covid RATs
In short, being careful to not throw too much cash at this as there may not be product demand.
The last line of the announcement before the CEO quote is...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
2.7¢ |
Change
0.000(0.00%) |
Mkt cap ! $20.21M | |||
| Open | High | Low | Value | Volume |
| 2.7¢ | 2.7¢ | 2.6¢ | $24.66K | 945.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 315442 | 2.6¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 2.7¢ | 1463859 | 3 |
View Market Depth
| Last trade - 15.59pm 24/06/2025 (20 minute delay) ? |
| LDX (ASX) Chart |